Extract from the Register of European Patents

EP Citations: EP2540294

Cited inSearch
Type:Patent literature
Publication No.:WO2007031887  [XYI]
 (NICHOLAS PIRAMAL INDIA LTD et al.) [X] 1,2,4,11,13 * page 19; table 7 *[Y] 7-10,12 [I] 3,5,6
Type:Patent literature
Publication No.:EP2140867  [Y]
 (DAIICHI SANKYO CO LTD et al.) [Y] 7-10,12 * page 3, paragraphs 6-10 * * page 4, paragraph 11 * * page 5, paragraphs 13-17 * * page 6, paragraphs 18-19 * * page 7, paragraph 31 * * page 11; table 2 *
Cited inby applicant
Type:Patent literature
Publication No.:JP2006507216  
Type:Patent literature
Publication No.:JP2004518676  
Type:Patent literature
Publication No.:WO2004058715  
Type:Patent literature
Publication No.:WO03000657  
Type:Patent literature
Publication No.:WO03000680  
Type:Patent literature
Publication No.:WO03016302  
Type:Non-patent literature
Publication information:  WFO DRUG INFORMATION, vol. 18, no. 3, 2004, pages 260
Type:Non-patent literature
Publication information:  SUSANNE R ET AL., J. MED. CHEM., vol. 48, 2005, pages 5900 - 5908
Type:Non-patent literature
Publication information:  BLOOD, 2003, pages 102
Type:Non-patent literature
Publication information:  WFO DRUG INFORMATION, vol. 20, no. 1, 2006, pages 38
Type:Non-patent literature
Publication information:  PINTO DJP; ORWAT MJ; LAM PYS ET AL.: "Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa", J. MED. CHEM., vol. 50, no. 22, 2007, pages 5339 - 56, XP007915445, DOI: doi:10.1021/jm070245n
DOI: http://dx.doi.org/10.1021/jm070245n
Type:Non-patent literature
Publication information:  WFO DRUG INFORMATION, vol. 22, no. 3, 2008, pages 226 - 227
Type:Non-patent literature
Publication information:  ZHANG P; HUANG W; ZHU BY ET AL.: "Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor", BIOORG MED. CHEM. LETT., vol. 19, no. 8, 2009, pages 2179 - 85, XP026079433, DOI: doi:10.1016/j.bmcl.2009.02.111
DOI: http://dx.doi.org/10.1016/j.bmcl.2009.02.111
Type:Non-patent literature
Publication information:  S. TAKEHANA ET AL., JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. 1, 2000, pages 213P
Type:Non-patent literature
Publication information:  T. KAYAHARA ET AL., JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. 1, 2000, pages 213P
Type:Non-patent literature
Publication information:  XVIITH CONGRESS OF THE INTERNATIONAL SOCIETY FOR THROMBOSIS AND HAEMOSTASIS, WASHINGTON D. C., USA, 14 August 1999 (1999-08-14)
Type:Non-patent literature
Publication information:  GENERATING GREATER VALUE FROM OUR PRODUCTS AND PIPELINE. AVENTIS SA COMPANY PRESENTATION, 5 February 2004 (2004-02-05)
Type:Non-patent literature
Publication information:  WFO DRUG INFORMATION, vol. 16, no. 3, 2002, pages 257
Type:Non-patent literature
Publication information:  AMERICAN CHEMICAL SOCIETY-226TH NATIONAL MEETING, NEW YORK CITY, NY, USA, 2003
Type:Non-patent literature
Publication information:  J. R. PRUITT ET AL., J. MED. CHEM., vol. 46, 2003, pages 5298 - 5313
Type:Non-patent literature
Publication information:  S. YOUNG, MEDICINAL CHEMISTRY-12TH RSC-SCI SYMPOSIUM, 7 September 2003 (2003-09-07)
Type:Non-patent literature
Publication information:  M. WILEY ET AL., 228TH ACS NATIONAL MEETING, PHILADELPHIA, 22 August 2004 (2004-08-22), pages 252,254